Research suggests results-based contracts (RBCs)—also known as value-based contracts—have the potential to lower costs for patients and the health system. According to a recent analysis, these types of arrangements can reduce copays for patients by an average of 28 percent and, if they reduce diabetes costs by five percent, could save $12 billion dollars for the United States each year.
Despite the promise of these innovative payment approaches, regulations instituted before innovative contracting approaches were developed can create uncertainty for biopharmaceutical companies looking to pursue RBCs and can discourage them from entering into these beneficial agreements.
Learn more at www.phrma.org/value-collaborative.
Katie Koziara Katie is a manager of public affairs at PhRMA focusing on the cost and value of medicines. She previously ran the social media strategy for a D.C.-based non-profit working on federal management and leadership issues. Outside the office, Katie can be found running on the mall, brunching with friends and cheering on the Michigan Wolverines.
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
